Inhalable Medicines for Severe Lung Diseases: Lyn Baranowski on The Long Run

Lyn Baranowski is today’s guest on The Long Run.

Lyn is the CEO of Boston-based Avalyn Pharma. The company is developing inhalable drugs for rare, severe lung diseases, such as pulmonary fibrosis and other interstitial lung diseases.

Lyn Baranowski, CEO, Avalyn Pharma

Avalyn has taken a couple of small molecules that are given orally, and remade them into inhalable drugs so they can be more effectively delivered where they need to go, deep in the lungs. By concentrating delivery, the idea is that Avalyn will be able to lower the doses needed and make treatments that are easier for patients to tolerate over the long term.

In this episode you’ll hear Lyn’s enthusiasm for developing better treatments for respiratory diseases. It’s one of the therapeutic areas that doesn’t capture a lot of news coverage, but lung diseases of one kind of another affect many people.

The Long Run is sponsored by:

Under unprecedented time and cost pressures, many life sciences teams have reached for off-the-shelf AI tools to stay afloat. Yet they have discovered that generic AI tools introduce new risks, such as hallucination. Tools that cannot withstand scientific or regulatory scrutiny are a liability in MLR review, portfolio committees, and investment decisions where every claim must be traceable to a source.

More than isolated tools, teams need a purpose-built intelligence layer designed for the rigor that the industry demands. Across life sciences functions, platforms like AlphaSense are streamlining the entire decision cycle. Download this report that covers the top AI use cases that have transformed how the industry’s leading teams reach defensible answers.

Quick question: when was the last time a CRO told you what something costs before you signed an NDA, sat through two scoping calls, and waited a week for a Scope of Work? In bioanalysis, pricing gets treated like a closely-guarded secret. Dash Bio thinsk that’s backward. It publishes pricing publicly, on its website, and even has a calculator that shows how the price changes if you redesign your study. You can see what your study costs before you talk to a human being. No surprise line items, no “it depends”, no games. Dash was built to be the bioanalysis company that’s actually straightforward to work with: transparent pricing, guaranteed timelines, and data in days, not months.

If you’re tired of pricing that feels like a negotiation every single time, run your bioanalysis with Dash. Visit dash.bio/pricing and see exactly how much your next bioanalysis study will cost.

Now please enjoy this conversation with Lyn Baranowski on The Long Run.